domingo, 4 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 12, 2026

Franklin Lexington Private Equities Secondaries Strategy Exceeds $3.5 Billion in Assets Under Management Globally Within First Year

View original at finance.yahoo.com
Franklin Lexington Private Equities Secondaries Strategy Exceeds $3.5 Billion in Assets Under Management Globally Within First Year Rapid Growth in Firm’s First Continuously Offered Private Equity Secondaries Strategy Highlights Strong Demand from Global Wealth Channel SAN MATEO, Calif., February 12, 2026--(BUSINESS WI…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We believe the secondary market offers compelling long-term growth potential

    80% confidence
  • We remain committed to our goal of delivering innovative solutions that empower financial advisors and their clients to achieve long-term goals with greater diversification and potential for enhanced returns

    80% confidence
  • We are proud to partner with Franklin Templeton on this innovative strategy and broaden access to the secondary market for a wider range of investors

    80% confidence
  • This milestone demonstrates the strong demand for high-quality private markets exposure and validates our industry-leading secondary platform

    80% confidence
  • This milestone marks not only an exciting chapter for the Franklin Lexington PE secondaries strategy, but also a powerful validation of the momentum building across the global Franklin Templeton Private Markets platform

    80% confidence

Citado nestas reportagens da Via News

O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,340 documentos-fonte arquivados
Consulte estes dados → isubstrate.com